https://scholars.lib.ntu.edu.tw/handle/123456789/161501
標題: | Molecular-targeted Therapy for Chemotherapy-refractory Gastric Cancer: A Case Report and Literature Review | 作者: | Kuo, Hung-Yang Yeh, Kun-Huei |
關鍵字: | Gastric cancer;trastuzumab;chemotherapy;refractory;ramucirimab;targeted therapy | 公開日期: | 2014 | 卷: | 34 | 期: | 7 | 起(迄)頁: | 3695-3699 | 來源出版物: | Anticancer Res. | 摘要: | The prognosis of advanced gastric cancer (AGC) remains poor despite therapeutic advances in recent decades. Several recent positive phase III trials established the efficacy of second-line chemotherapy for metastatic gastric cancer in prolonging overall survival. However, malnutrition and poor performance of AGC in late stages usually preclude such patients from intensive treatment. Many targeted-therapies failed to show a significant survival benefit in AGC, but have regained attention after the positive result of ramucirumab was announced last year. Among all targeted agents, only trastuzumab, a monoclonal antibody against Human epidermal growth factor receptor-2 (HER2) protein, has been proven as having survival benefit by addition to first-line chemotherapy. Herein we reported a patient who benefited from adding trastuzumab to the same second-line combination chemotherapy (paclitaxel, 5-fluorouracil, and leucovorin) upon progression of bulky liver metastases. At least five months of progression-free survival were achieved without any additional toxicity. We also reviewed literature of molecularly-targeted therapy for chemotherapy-refractory gastric cancer, including several large phase III trials (REGARD, GRANITE-1, EXPAND, and REAL-3) published in 2013-2014. |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/280060 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。